Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750600 | 0.95 | ALOX5 (0.43) | BRAFTNKSKDRFLT3PARP1 | |
| SCHEMBL1752472 | 0.92 | KDR (0.50) | BRAFTNKSKDRFLT3PARP1 | |
| SCHEMBL1750035 | 0.90 | MAPT (0.42) | KDRPARP1GSK3AGSK3BDYRK1A | |
| SCHEMBL1750623 | 0.88 | CDK5 (0.40) | KDRGSK3AGSK3BDYRK1AMAOA | |
| SCHEMBL1750859 | 0.87 | KDR (0.47) | BRAFTNKSKDRFLT3PARP1 | |
| SCHEMBL5563039 | 0.87 | GSK3A (0.43) | KDRFLT3GSK3AGSK3BDYRK1A | |
| SCHEMBL1752097 | 0.83 | GSK3A (0.54) | KDRFLT3GSK3AGSK3BDYRK1A | |
| SCHEMBL1750603 | 0.83 | KDR (0.47) | KDRFLT3DYRK1A | |
| SCHEMBL1750229 | 0.82 | KDR (0.55) | KDRFLT3PARP1DYRK1A | |
| SCHEMBL1751186 | 0.82 | DYRK1A (0.42) | TNKSPARP1GSK3AGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7507734-B2 | Pyridazinone derivatives | AVENTIS PHARMA S.A. (FR) | 2009-03-24 | — | — | US | disclosed |
| US-7507734-B2 | Pyridazinone derivatives | AVENTIS PHARMA S.A. (FR) | 2009-03-24 | — | — | US | disclosed |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | BRAF 288/4885TNKS 397/4885KDR 1907/4885 |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | BRAF 147/4885TNKS 553/4885KDR 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.